ARMATA PHARMACEUTICALS INC (ARMP) competitors & alternatives
Health Care · NYSE American
ARMATA PHARMACEUTICALS INC (ARMP)'s top competitors and alternatives — its most similar public companies — include INTELLIA THERAPEUTICS INC (NTLA), CRISPR THERAPEUTICS AG (CRSP), Insmed (INSM), ELECTROMED INC (ELMD), SIONNA THERAPEUTICS INC (SION), Vertex Pharmaceuticals (VRTX), 4D MOLECULAR THERAPEUTICS INC (FDMT), ARCTURUS THERAPEUTICS HOLDINGS INC (ARCT), GYRE THERAPEUTICS INC (GYRE), VAXCYTE INC (PCVX), INNOVIVA INC (INVA) and TREVI THERAPEUTICS INC (TRVI). These are ARMATA PHARMACEUTICALS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top ARMP competitors & alternatives
-
INTELLIA THERAPEUTICS INCNTLAHealth Care
CRISPR-based genome editing company developing in vivo therapies for rare genetic diseases including hereditary angioedema and ATTR amyloidosis.
$11.13 (as of 2026-07-22) · market cap $1.6B
-
CRISPR THERAPEUTICS AGCRSPHealth Care
CRISPR Therapeutics develops gene-editing medicines using CRISPR/Cas9 technology, with the first approved CRISPR therapy (CASGEVY) for sickle cell disease and…
$47.24 (as of 2026-07-22) · market cap $4.6B
-
InsmedINSMHealth Care
A biopharmaceutical company with approved rare respiratory therapies (ARIKAYCE for MAC lung disease, BRINSUPRI for bronchiectasis) and a pipeline in…
$106.64 (as of 2026-07-22) · market cap $23.4B
-
ELECTROMED INCELMDHealth Care
Electromed provides innovative airway clearance therapy through its SmartVest systems to help patients with chronic pulmonary conditions breathe easier.
$39.52 (as of 2026-07-22) · market cap $336M
-
SIONNA THERAPEUTICS INCSIONHealth Care
A clinical-stage biotech pioneering the first drugs to directly stabilize CFTR's NBD1 domain, tackling the "undruggable" target in cystic fibrosis.
$45.03 (as of 2026-07-22) · market cap $2.1B
-
Vertex PharmaceuticalsVRTXHealth Care
Vertex Pharmaceuticals develops transformative medicines for serious genetic diseases, with a dominant pipeline anchored in cystic fibrosis treatments and…
$472.57 (as of 2026-07-22) · market cap $121.4B
-
4D MOLECULAR THERAPEUTICS INCFDMTHealth Care
4D Molecular Therapeutics is a clinical-stage biotech developing AAV-based gene therapies for ophthalmic and respiratory diseases using its proprietary…
$10.96 (as of 2026-07-22) · market cap $573M
-
ARCTURUS THERAPEUTICS HOLDINGS INCARCTHealth Care
Arcturus Therapeutics develops self-amplifying mRNA therapeutics and vaccines, with the first approved sa-mRNA COVID vaccine (KOSTAIVE) generating revenue…
$5.93 (as of 2026-07-22) · market cap $168M
-
GYRE THERAPEUTICS INCGYREHealth Care
A China-based biopharmaceutical company generating revenue from approved antifibrotic treatments while advancing late-stage candidates for liver and other…
$5.94 (as of 2026-07-22) · market cap $667M
-
VAXCYTE INCPCVXHealth Care
Vaxcyte engineers next-generation bacterial vaccines using cell-free protein synthesis to create broader-spectrum, more immunogenic alternatives to existing…
$56.00 (as of 2026-07-22) · market cap $8.1B
-
INNOVIVA INCINVAHealth Care
A diversified biopharmaceutical company combining respiratory royalties from GSK blockbusters (BREO, ANORO) with a growing critical care and infectious disease…
$21.43 (as of 2026-07-22) · market cap $1.6B
-
TREVI THERAPEUTICS INCTRVIHealth Care
Trevi Therapeutics is a clinical-stage biotech developing Haduvio, an oral, non-scheduled dual-action opioid receptor drug, to treat chronic cough associated…
$17.36 (as of 2026-07-22) · market cap $2.5B
Not quite? Describe exactly what you want →
Peers are ARMATA PHARMACEUTICALS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: ARMATA PHARMACEUTICALS INC (ARMP).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.